Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo, Stephen R.D. Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017
Cited by 381 works. doi:10.1016/s1470-2045(17)30688-5
Authors
- Angelo Di Leo
- Stephen R.D. Johnston
- Keun Seok Lee
- Eva Ciruelos
- Per Eystein Lønning
- Wolfgang Janni
- Ruth M O'Regan
- Marie‐Ange Mouret‐Reynier
- Dimitar Nikolaev Kalev
- Daniel Egle
- Tibor Csőszi
- Roberto Bordonaro
- Thomas W. Decker
- Vivianne C. G. Tjan‐Heijnen
- Sibel H. Blau
- Alessio Schirone
- Denis Weber
- Mona El-Hashimy
- Bharani Dharan
- Dalila B. Sellami
References
- Comprehensive molecular portraits of human breast tumours
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
- Perturbations of the AKT signaling pathway in human cancer